Epilepsy is a clinical multiaxial diagnosis.
Epileptic seizure is a transient occurrence of signs/symptoms brought about by abnormal excessive or synchronous neuronal activity in the brain.
It is recommended that all patients having a first seizure be referred as soon as possible to a specialist to ensure accurate and early diagnosis and initiation of treatment appropriate to the needs of the patients.
Child-onset epilepsy may negatively affect social outcomes, and individuals who still experience seizure as adults are least likely to start a family and have trouble conceiving, a study from Finland has found.
Midazolam nasal spraydelivers prompt and prolonged seizure control with a favourable safety profile in the outpatient treatment of patients experiencing a seizure cluster, according to the results of the phase III ARTEMIS-1* trial.
New drug applications approved by US FDA as of 16 - 31 May 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
A low sodium concentration in the blood is commonly observed in patients with epilepsy, with moderate and severe hyponatraemia associated with reduced bone mineral density in the lumbar spine, a study has found.
A broad range of peripheral infections, including those of the central nervous system, appears to be associated with a heightened risk of developing epilepsy, potentially due to inflammatory processes affecting the brain, according to a study.